Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 5/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.72 |
| ▸ | TTR | P02766 | 4/20 | 0.72 |
| ▸ | NQO2 | P16083 | 4/20 | 0.70 |
| ▸ | ESR1 | P03372 | 3/20 | 0.70 |
| ▸ | ABL1 | P00519 | 3/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.70 |
| ▸ | BCR | P11274 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.70 |
| ▸ | AHR | P35869 | 2/20 | 0.70 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.70 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.70 |
| ▸ | TUBB | P07437 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resveratrol 4'-Methyl Ether SCHEMBL4732963 | 1.00 | PTGS2 (1.00) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| Resveratrol 4'-Methyl Ether SCHEMBL563262 | 1.00 | PTGS2 (1.00) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL15026080 | 0.92 | PTGS2 (0.85) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL29652111 | 0.92 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL2516446 | 0.92 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL2516449 | 0.92 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL29662231 | 0.92 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL12307322 | 0.89 | PTGS2 (0.79) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL8396878 | 0.87 | PTGS2 (0.77) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL12567384 | 0.87 | PTGS2 (0.77) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4655410-A2 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | Symrise AG (DE) | 2025-12-03 | — | — | EP | claimed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | claimed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2024156879-A2 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | SYMRISE AG (DE) | 2024-08-02 | — | — | WO | claimed |
| WO-2024156359-A1 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | SYMRISE AG (DE) | 2024-08-02 | — | — | WO | claimed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | claimed |
| US-20200397744-A1 | COMPOSITIONS COMPRISING CO-CRYSTALS OF STILBENOIDS AND CANNABINOIDS | NEUTRISCI INTERNATIONAL INC. (CA) | 2020-12-24 | — | — | US | claimed |
| EP-3634430-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2020-04-15 | — | — | EP | claimed |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | KINTAI THERAPEUTICS, INC. | 2020-04-02 | — | — | US | claimed |
| CN-110869024-A | Multi-biological agents and methods of use thereof | 旗舰创业创新五公司 | 2020-03-06 | — | — | CN | claimed |
| WO-2019153088-A1 | COMPOSITIONS COMPRISING CO-CRYSTALS OF STILBENOIDS AND CANNABINOIDS | NEUTRISCI INTERNATIONAL INC. (CA) | 2019-08-15 | — | — | WO | claimed |
| WO-2018226732-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2018-12-13 | — | — | WO | claimed |
| EP-2679243-B1 | Co-precipitate of one or more stilbene polyphenols in lamellar anionic solids, it's applications and related preparation method | FIORETTI BERNARD (IT) | 2017-05-24 | — | — | EP | claimed |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-07-12 | — | — | US | claimed |
| US-20110256115-A1 | HYDROSOLUBLE [6)O-ALPHA-D-GLCP-(1->]N-6-O-BETA-D-GLCP-(1->-PHENOLIC DERIVATIVES WITH DERMOCOSMETIC, NUTRITIONAL AND THERAPEUTIC APPLICATIONS, AND COMPOSITIONS CONTAINING SAID WATER SOLUBLE COMPOUNDS | LIBRAGEN (FR) | 2011-10-20 | — | — | US | claimed |
| EP-2202237-A1 | Hydrosoluble [6)-O-alpha-d-glcp-(1->]n-6-o-bêta-d-glcp-(1->-phenllic derivatives with dermocosmetic, nutritional and therapeutic applications, and compositions containing said water soluble compounds | Libragen (FR) | 2010-06-30 | — | — | EP | claimed |
| US-20080139650-A1 | Fungicidally Active Polymer Dispersions And Use Thereof | CELANESE EMULSIONS GMBH (DE) | 2008-06-12 | — | — | US | claimed |
| WO-2008070872-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-06-12 | — | — | WO | claimed |
| EP-4747367-A1 | NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES | Symrise AG (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743071-A2 | DIPHENYLETHYLENE COMPOUNDS AND COMPOSITIONS THEREOF | INNOVENE INC. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12569459-B2 | Compositions and methods for treating pulmonary edema or lung inflammation | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4655410-A2 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | Symrise AG (DE) | 2025-12-03 | — | — | EP | disclosed |
| EP-4595776-A1 | NUTRITIONAL COMPOSITION FOR CANCER PATIENTS AND ELDERLY SUBJECTS | Pasqualetti, Giuseppe (IT) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025017042-A1 | NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES | SYMRISE AG (DE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025016533-A1 | NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES | SYMRISE AG (DE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025015023-A2 | DIPHENYLETHYLENE COMPOUNDS AND COMPOSITIONS THEREOF | INNOVENE, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | disclosed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20240350406-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | UNIV MINNESOTA (US) | 2024-10-24 | — | — | US | disclosed |
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024156879-A2 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | SYMRISE AG (DE) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024156359-A1 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | SYMRISE AG (DE) | 2024-08-02 | — | — | WO | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024108201-A2 | CANNABIGEROLIC ACID (CBGA) AND CANNABIGEROL (CBG) DERIVED PRODUCTS AND METHODS OF USE | Bazelet Health Systems, Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-111728962-B | Resveratrol derivative and medical application thereof in resisting fibrosis | 绍兴君科臻元医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240082270-A1 | CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USE | BAZELET HEALTH SYSTEMS INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-11883528-B2 | Compositions and methods for treating pulmonary edema or lung inflammation | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2024018469-A1 | A COMBINATION FOR TREATING A RETINAL DISEASE | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2024-01-25 | — | — | WO | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230145555-A1 | COMPOSITION COMPRISING RESVERATROL | GALENUS G.H. AG (CH) | 2023-05-11 | — | — | US | disclosed |
| US-20230147865-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2023-05-11 | — | — | US | disclosed |
| US-20230050861-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | UNIV MINNESOTA (US) | 2023-02-16 | — | — | US | disclosed |
| EP-4132484-A1 | COMPOSITION COMPRISING RESVERATROL | Galenus G.H. AG (CH) | 2023-02-15 | — | — | EP | disclosed |
| EP-4126104-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | Regents of the University of Minnesota (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115551569-A | Compositions and methods for treating pulmonary edema or pneumonia | 明尼苏达大学董事会 | 2022-12-30 | — | — | CN | disclosed |
| US-11458094-B2 | Compositions and methods for treating pulmonary edema or lung inflammation | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220265775-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | UNIV MINNESOTA (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220160649-A1 | PHARMACEUTICAL COMPOSITION | DOBMEYER RITA (CH) | 2022-05-26 | — | — | US | disclosed |
| EP-3941449-A1 | PHARMACEUTICAL COMPOSITION | Dobmeyer, Rita (CH) | 2022-01-26 | — | — | EP | disclosed |
| CN-113924084-A | Pharmaceutical composition | 瑞塔·多布迈尔 | 2022-01-11 | — | — | CN | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-11045402-B2 | Hair cosmetic composition | KAO CORPORATION (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801587-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10959925-B2 | Hair cosmetic composition | KAO CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
| US-20210085640-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2021024041-A1 | CONTROLLED RELEASE DRUG DIMERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-02-11 | — | — | WO | disclosed |
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200397744-A1 | COMPOSITIONS COMPRISING CO-CRYSTALS OF STILBENOIDS AND CANNABINOIDS | NEUTRISCI INTERNATIONAL INC. (CA) | 2020-12-24 | — | — | US | disclosed |
| WO-2020187803-A1 | PHARMACEUTICAL COMPOSITION | DOBMEYER RITA (CH) | 2020-09-24 | — | — | WO | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| EP-3634430-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | KINTAI THERAPEUTICS, INC. | 2020-04-02 | — | — | US | disclosed |
| CN-110869024-A | Multi-biological agents and methods of use thereof | 旗舰创业创新五公司 | 2020-03-06 | — | — | CN | disclosed |
| US-10426742-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190290564-A1 | HAIR COSMETIC COMPOSITION | KAO CORPORATION (JP) | 2019-09-26 | — | — | US | disclosed |
| US-20190254943-A1 | HAIR COSMETIC COMPOSITION | KAO CORPORATION (JP) | 2019-08-22 | — | — | US | disclosed |
| WO-2019153088-A1 | COMPOSITIONS COMPRISING CO-CRYSTALS OF STILBENOIDS AND CANNABINOIDS | NEUTRISCI INTERNATIONAL INC. (CA) | 2019-08-15 | — | — | WO | disclosed |
| US-20190224093-A1 | HAIR COSMETIC COMPOSITION | KAO CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20190125052-A1 | METHOD FOR TREATING HAIR | KAO CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3463265-A1 | HAIR COSMETIC COMPOSITION | Kao Corporation (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3463266-A1 | HAIR COSMETIC COMPOSITION | Kao Corporation (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3463267-A1 | HAIR COSMETIC COMPOSITION | Kao Corporation (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3463264-A1 | METHOD FOR TREATING HAIR | Kao Corporation (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2018226732-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| US-9981895-B1 | Compositions and methods of synthesizing arachidin-3 from resveratrol | Parnative Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9861564-B2 | Valeric acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT, LLC (US) | 2018-01-09 | — | — | US | disclosed |
| WO-2017207768-A1 | METHOD FOR TREATING HAIR | KAO CORPORATION (JP) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017207767-A1 | HAIR COSMETIC COMPOSITION | KAO CORPORATION (JP) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017207799-A1 | HAIR COSMETIC COMPOSITION | KAO CORPORATION (JP) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017207786-A1 | HAIR COSMETIC COMPOSITION | KAO CORPORATION (JP) | 2017-12-07 | — | — | WO | disclosed |
| US-9782335-B2 | Malic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2786981-B1 | Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof | UNIV CHINA MEDICAL (TW) | 2017-08-16 | — | — | EP | disclosed |
| EP-3178809-A1 | HYBRID MOLECULE WITH STRUCTURAL AND ACTIVITY ELEMENTS OF RESVERATROL AND DIALLYL SULFIDE | Albert-Ludwigs-Universität Freiburg (DE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2679243-B1 | Co-precipitate of one or more stilbene polyphenols in lamellar anionic solids, it's applications and related preparation method | FIORETTI BERNARD (IT) | 2017-05-24 | — | — | EP | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-20160303016-A1 | Valeric Acid Esters Of Resveratrol And Cosmetic Compositions | ELC MAN LLC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2016-10-13 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| EP-2445511-B1 | SKIN REPAIR COMPOSITIONS COMPRISING CIRCADIAN GENE ACTIVATORS AND A SYNERGISTIC COMBINATION OF SIRT1 GENE ACTIVATORS | ELC MAN LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160229791-A1 | Malic Acid Esters Of Resveratrol And Cosmetic Compositions | ELC MAN LLC (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3031461-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9358194-B2 | Succinic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9326930-B2 | Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions | NEOCUTIS S.A. (CH) | 2016-05-03 | — | — | US | disclosed |
| US-9295621-B2 | Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant | ELC MANAGEMENT LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-9266813-B2 | Stilbenoid compound as inhibitor for squamous carcinoma and hepatoma and uses thereof | CHINA MEDICAL UNIVERSITY (TW) | 2016-02-23 | — | — | US | disclosed |
| US-9266813-B2 | Stilbenoid compound as inhibitor for squamous carcinoma and hepatoma and uses thereof | CHINA MEDICAL UNIVERSITY (TW) | 2016-02-23 | — | — | US | disclosed |
| EP-2362226-B1 | Diagnostic method for neurodegenerative diseases based on measurement of SIRT1 levels or activity | HARVARD COLLEGE (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2362226-B1 | Diagnostic method for neurodegenerative diseases based on measurement of SIRT1 levels or activity | HARVARD COLLEGE (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20160038389-A1 | Succinic Acid Esters Of Resveratrol And Cosmetic Compositions | ELC MAN LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160030321-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | NEOCUITIS S A (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9180316-B2 | Butyric acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9162083-B2 | Linoleic and Linolenic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | US | disclosed |
| US-9028887-B2 | Method improve spatial memory via pterostilbene administration | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2015-01-22 | — | — | US | disclosed |
| US-8921614-B1 | Selective deoxygenation of hydroxybenzaldehydes | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921614-B1 | Selective deoxygenation of hydroxybenzaldehydes | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2014-12-30 | — | — | US | disclosed |
| US-8912234-B2 | Composition containing resveratrol and/or derivatives thereof and plant oil, process for producing said composition, nutraceutical and/or pharmaceutical product, and method for enhancing the potential of resveratrol | UNIAO Brasileria de Educacao e Assistencia—Mantenedora da PUCRS (BR) | 2014-12-16 | — | — | US | disclosed |
| EP-2200597-B1 | METHOD TO AMELIORATE OXIDATIVE STRESS AND IMPROVE WORKING MEMORY VIA PTEROSTILBENE ADMINISTRATION | US AGRICULTURE (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2200597-B1 | METHOD TO AMELIORATE OXIDATIVE STRESS AND IMPROVE WORKING MEMORY VIA PTEROSTILBENE ADMINISTRATION | US AGRICULTURE (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140303241-A1 | STILBENOID COMPOUND AS INHIBITOR FOR SQUAMOUS CARCINOMA AND HEPATOMA AND USES THEREOF | ANNCARE BIO-TECH CENTER INC. (TW) | 2014-10-09 | — | — | US | disclosed |
| US-20140303241-A1 | STILBENOID COMPOUND AS INHIBITOR FOR SQUAMOUS CARCINOMA AND HEPATOMA AND USES THEREOF | ANNCARE BIO-TECH CENTER INC. (TW) | 2014-10-09 | — | — | US | disclosed |
| EP-2786981-A1 | Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof | AnnCare Bio-Tech Center Inc. (TW) | 2014-10-08 | — | — | EP | disclosed |
| US-8846724-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140256827-A1 | Method Improve Spatial Memory Via Pterostilbene Administration | WESTERN ALLIANCE BANK | 2014-09-11 | — | — | US | disclosed |
| EP-1853349-B1 | Composition for treating mental health disorders | LINES THOMAS CHRISTIAN (LU) | 2014-09-03 | — | — | EP | disclosed |
| US-8809400-B2 | Method to ameliorate oxidative stress and improve working memory via pterostilbene administration | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140134117-A1 | Butyric Acid Esters Of Resveratrol And Cosmetic Compositions | MAES DANIEL H (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140127146-A1 | Linoleic And Linolenic Acid Esters Of Resveratrol And Cosmetic Compositions | MAES DANIEL H (US) | 2014-05-08 | — | — | US | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8703161-B2 | Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators | ELC MANAGEMENT, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575217-B2 | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-11-05 | — | — | US | disclosed |
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-10-24 | — | — | US | disclosed |
| US-20130281413-A1 | Salicylate Conjugates Useful For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-10-24 | — | — | US | disclosed |
| US-8546342-B2 | Composition for treating mental health disorders | LINES, THOMAS CHRISTIAN (CH) | 2013-10-01 | — | — | US | disclosed |
| US-8546342-B2 | Composition for treating mental health disorders | LINES, THOMAS CHRISTIAN (CH) | 2013-10-01 | — | — | US | disclosed |
| US-8476248-B2 | Process for the preparation of a water-soluble complex having resveratrol compounds; products comprising said complex; and uses thereof | Uniao Brasileira de Educacao e Assistencia—Mantenedora da PUCRS (BR) | 2013-07-02 | — | — | US | disclosed |
| US-8476248-B2 | Process for the preparation of a water-soluble complex having resveratrol compounds; products comprising said complex; and uses thereof | Uniao Brasileira de Educacao e Assistencia—Mantenedora da PUCRS (BR) | 2013-07-02 | — | — | US | disclosed |
| US-8461200-B2 | Salicylic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2013-06-11 | — | — | US | disclosed |
| US-8426369-B2 | Prevention and treatment of colon cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20130040920-A1 | COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL | UNIAO Brasileira de Educacao e Assistencia- Matenedora da PUCRS (BR) | 2013-02-14 | — | — | US | disclosed |
| US-8362076-B2 | Ascorbic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-8344024-B2 | Anhydrous cosmetic compositions containing resveratrol derivatives | ELC MANAGEMENT LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120288461-A1 | Ascorbic Acid Esters of Resveratrol and Cosmetic Compositions | MAES DANIEL H (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120288460-A1 | Salicylic Acid Esters of Resveratrol and Cosmetic Compositions | MAES DANIEL H (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120225833-A1 | COMPOSITION FOR TREATING MENTAL HEALTH DISORDERS | Quercegne Pharmaceuticals LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225833-A1 | COMPOSITION FOR TREATING MENTAL HEALTH DISORDERS | Quercegne Pharmaceuticals LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-07-12 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20120035272-A1 | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120029065-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-02-02 | — | — | US | disclosed |
| US-8084496-B2 | Resveratrol ferulate compounds and compositions | ELC MANAGEMENT LLC (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2381918-A2 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | Neocutis SA (CH) | 2011-11-02 | — | — | EP | disclosed |
| EP-2379576-A1 | HYDROSOLUBLE [6)-O-alpha-D-GLCP-(1->]n-6-O-beta-D-GLCP-(1->-PHENOLIC DERIVATIVES WITH DERMOCOSMETIC, NUTRITIONAL AND THERAPEUTIC APPLICATIONS, AND COMPOSITIONS CONTAINING SAID WATER SOLUBLE COMPOUNDS | Libragen (FR) | 2011-10-26 | — | — | EP | disclosed |
| US-20110256115-A1 | HYDROSOLUBLE [6)O-ALPHA-D-GLCP-(1->]N-6-O-BETA-D-GLCP-(1->-PHENOLIC DERIVATIVES WITH DERMOCOSMETIC, NUTRITIONAL AND THERAPEUTIC APPLICATIONS, AND COMPOSITIONS CONTAINING SAID WATER SOLUBLE COMPOUNDS | LIBRAGEN (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110250251-A1 | Cosmetic Methods And Compositions For Repairing Human Skin | MAES DANIEL H | 2011-10-13 | — | — | US | disclosed |
| US-8017634-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-09-13 | — | — | US | disclosed |
| EP-2361618-A2 | Compositions for treating or preventing obesity and insulin resistance disorders | The President and Fellows of Harvard College (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2362226-A1 | Diagnostic method for neurodegenerative diseases based on measurement of SIRT1 levels or activity | The President and Fellows of Harvard College (US) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011097691-A1 | COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL | UNIÃO BRASILEIRA DE EDUCAÇÁO E ASSISTÊNCIA - MANTENEDORA DA PUCRS (BR) | 2011-08-18 | — | — | WO | disclosed |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | KENT STATE UNIVERSITY (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | KENT STATE UNIVERSITY (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | KENT STATE UNIVERSITY (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2289504-A2 | SIRT1 modulators for manipulating cell/organism lifespan/stress response | President and Fellows of Harvard College (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2289504-A2 | SIRT1 modulators for manipulating cell/organism lifespan/stress response | President and Fellows of Harvard College (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100310615-A1 | COMPOSITIONS COMPRISING STILBENE POLYPHENOL DERIVATIVES AND USE THEREOF FOR COMBATING THE AGEING OF LIVING ORGANISMS AND DISEASES AFFECTING SAME | CAUDALIE (FR) | 2010-12-09 | — | — | US | disclosed |
| US-20100310615-A1 | COMPOSITIONS COMPRISING STILBENE POLYPHENOL DERIVATIVES AND USE THEREOF FOR COMBATING THE AGEING OF LIVING ORGANISMS AND DISEASES AFFECTING SAME | CAUDALIE (FR) | 2010-12-09 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2236131-A2 | Compositions for manipulating the lifespan and stress response of cells and organisms | President and Fellows of Harvard College (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010102245-A1 | SOLID DISPERSION COMPRISING RESVERATROL | UPSHER-SMITH LABORATORIES, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20100216879-A1 | Resveratrol Ferulate Compounds And Compositions | MAES DANIEL H | 2010-08-26 | — | — | US | disclosed |
| US-20100204179-A1 | Resveratrol complex and process for the preperation | UNIÃO BRASILEIRA DE EDUCAÇÃO E ASSISTÊNCIA - MANTENEDORA DA PUCRS (BR) | 2010-08-12 | — | — | US | disclosed |
| US-20100204179-A1 | Resveratrol complex and process for the preperation | UNIÃO BRASILEIRA DE EDUCAÇÃO E ASSISTÊNCIA - MANTENEDORA DA PUCRS (BR) | 2010-08-12 | — | — | US | disclosed |
| US-20100189795-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | NEOCUTIS S.A. (CH) | 2010-07-29 | — | — | US | disclosed |
| WO-2010083368-A2 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | NEOCUTIS SA (CH) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010072754-A1 | HYDROSOLUBLE [6)O-α-D-GLCP-(1→]n-6-O-β-D-GLCP-(1→-PHENOLIC DERIVATIVES WITH DERMOCOSMETIC, NUTRITIONAL AND THERAPEUTIC APPLICATIONS, AND COMPOSITIONS CONTAINING SAID WATER SOLUBLE COMPOUNDS | LIBRAGEN (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| EP-2202237-A1 | Hydrosoluble [6)-O-alpha-d-glcp-(1->]n-6-o-bêta-d-glcp-(1->-phenllic derivatives with dermocosmetic, nutritional and therapeutic applications, and compositions containing said water soluble compounds | Libragen (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-7732666-B1 | O-methyltransferase gene from sorghum cloning, expression, transformation and characterization | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732666-B1 | O-methyltransferase gene from sorghum cloning, expression, transformation and characterization | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2010-06-08 | — | — | US | disclosed |
| US-7705188-B2 | Structural modification of resveratrol: sodium resverastatin phosphate | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705188-B2 | Structural modification of resveratrol: sodium resverastatin phosphate | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100080845-A1 | Cosmetic Methods And Compositions For Repairing Human Skin | MAES DANIEL H | 2010-04-01 | — | — | US | disclosed |
| US-20100035885-A1 | COMPOSITIONS FOR MANIPULATING THE LIFESPAN AND STRESS RESPONSE OF CELLS AND ORGANISMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100028317-A1 | Skin Repair Compositions Comprising Circadian Gene Activators And A Synergistic Combination Of Sirt1 Gene Activators | ELC MANAGEMENT LLC | 2010-02-04 | — | — | US | disclosed |
| US-7544497-B2 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544497-B2 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090069444-A1 | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH E SECRETARY OF AGRICULTURE (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090047309-A1 | COSMETIC METHODS AND COMPOSITIONS FOR REPAIRING HUMAN SKIN | ELC MANAGEMENT LLC | 2009-02-19 | — | — | US | disclosed |
| US-20090035243-A1 | Anhydrous Cosmetic Compositions Containing Resveratrol Derivatives | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035240-A1 | Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035242-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Linear Or Branched Silicone | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035236-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035237-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
| WO-2009012551-A1 | RESVERATROL COMPLEX AND PROCESS FOR THE PREPERATION | UNIÄO BRASILEIRA DE EDUCAÇAO E ASSITENCIA-MANTENEDORA DA PUCRS (BR) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008157787-A2 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080139650-A1 | Fungicidally Active Polymer Dispersions And Use Thereof | CELANESE EMULSIONS GMBH (DE) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070872-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008028098-A2 | A NOVEL O-METHYLTRANSFERASE GENE FROM SORGHUM CLONING, EXPRESSION, TRANSFORMATION AND CHARACTERIZATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-1863461-A2 | SIRTUIN RELATED THERAPEUTICS AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES | The President and Fellows of Harvard College (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1850840-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | Sirtris Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1841415-A2 | USE OF SIRTUIN-ACTIVATING COMPOUNDS FOR TREATING FLUSHING AND DRUG INDUCED WEIGHT GAIN | Sirtris Pharmaceuticals, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060276416-A1 | Methods and compositions for treating flushing and drug induced weight gain | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006096780-A2 | SIRTUIN RELATED THERAPEUTICS AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006079021-A2 | USE OF SIRTUIN-ACTIVATING COMPOUNDS FOR TREATING FLUSHING AND DRUG INDUCED WEIGHT GAIN | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006076681-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1648437-A2 | SIRT1 MODULATORS FOR MANIPULATING CELL/ORGANISM LIFESPAN/STRESS RESPONSE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20060084135-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | BIOMOL INTERNATIONAL, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060025337-A1 | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-02-02 | — | — | US | disclosed |
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | NATIONAL INSTITUTES OF HEALTH | 2005-10-27 | — | — | US | disclosed |
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | NATIONAL INSTITUTES OF HEALTH | 2005-10-27 | — | — | US | disclosed |
| US-20050136537-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-06-23 | — | — | US | disclosed |
| US-20050096256-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005002555-A2 | SIRT1 MODULATORS FOR MANIPULATING CELL/ORGANISM LIFESPAN/STRESS RESPONSE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005002672-A2 | SIRT1 MODULATORS FOR MANIPULATING CELLS/ORGANISM LIFESPAN/STRESS RESPONSE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2003086414-A1 | STRUCTURAL MODIFICATION OF RESVERATROL: SODIUM RESVERASTATIN PHOSPHATE | ARIZONA BOARD OF REGENTS (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086414-A1 | STRUCTURAL MODIFICATION OF RESVERATROL: SODIUM RESVERASTATIN PHOSPHATE | ARIZONA BOARD OF REGENTS (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086414-A1 | STRUCTURAL MODIFICATION OF RESVERATROL: SODIUM RESVERASTATIN PHOSPHATE | ARIZONA BOARD OF REGENTS (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035243-A1 | Anhydrous Cosmetic Compositions Containing Resveratrol Derivatives | RB1, SIRT1, EP300 | PTGS2 3838/4885CYP1A1 1440/4885CYP1B1 902/4885 |
| US-20090035242-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Linear Or Branched Silicone | SQLE, SMURF1, PIK3R1 | PTGS2 3228/4885CYP1A1 2625/4885CYP1B1 1478/4885 |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | PTGS2 2561/4885CYP1A1 4665/4885CYP1B1 4592/4885 |
| US-20110256115-A1 | HYDROSOLUBLE [6)O-ALPHA-D-GLCP-(1->]N-6-O-BETA-D-GLCP-(1->-PHENOLIC DERIVATIVES WITH DERMOCOSMETIC, NUTRITIONAL AND THERAPEUTIC APPLICATIONS, AND COMPOSITIONS CONTAINING SAID WATER SOLUBLE COMPOUNDS | UGGT1, UGDH, CYP24A1 | PTGS2 1730/4885CYP1A1 333/4885CYP1B1 578/4885 |
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | PTGS2 169/4885CYP1A1 379/4885CYP1B1 223/4885 |
| US-20100035885-A1 | COMPOSITIONS FOR MANIPULATING THE LIFESPAN AND STRESS RESPONSE OF CELLS AND ORGANISMS | SIRT1, SIRT2, FOXO3 | PTGS2 2650/4885CYP1A1 4175/4885CYP1B1 4123/4885 |
| US-20130040920-A1 | COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL | GPR119, MAVS, SIRT1 | PTGS2 1099/4885CYP1A1 1104/4885CYP1B1 1838/4885 |
| US-20090069444-A1 | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration | GPX4, SQLE, PYGB | PTGS2 204/4885CYP1A1 747/4885CYP1B1 737/4885 |
| US-20220160649-A1 | PHARMACEUTICAL COMPOSITION | FGF23, FGFR3, FGFR2 | PTGS2 3287/4885CYP1A1 652/4885CYP1B1 633/4885 |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | PTGS2 1761/4885CYP1A1 1760/4885CYP1B1 1531/4885 |
| US-20140303241-A1 | STILBENOID COMPOUND AS INHIBITOR FOR SQUAMOUS CARCINOMA AND HEPATOMA AND USES THEREOF | HDGF, HCCS, HAVCR2 | PTGS2 1437/4885CYP1A1 3011/4885CYP1B1 1940/4885 |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | PTGS2 4658/4885CYP1A1 4722/4885CYP1B1 4471/4885 |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | PTGS2 3950/4885CYP1A1 3389/4885CYP1B1 3055/4885 |
| US-20100216879-A1 | Resveratrol Ferulate Compounds And Compositions | FER, FOLR1, FOLR2 | PTGS2 2446/4885CYP1A1 419/4885CYP1B1 764/4885 |
| US-11045402-B2 | Hair cosmetic composition | CUTA, GRHPR, POLR1C | PTGS2 1901/4885CYP1A1 778/4885CYP1B1 548/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | PTGS2 1761/4885CYP1A1 1760/4885CYP1B1 1531/4885 |
| US-20230145555-A1 | COMPOSITION COMPRISING RESVERATROL | VDR, ACE2, CYP2R1 | PTGS2 723/4885CYP1A1 2873/4885CYP1B1 3913/4885 |
| US-10959925-B2 | Hair cosmetic composition | CUTA, POLR1C, GRHPR | PTGS2 2392/4885CYP1A1 363/4885CYP1B1 264/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | PTGS2 3950/4885CYP1A1 3389/4885CYP1B1 3055/4885 |
| US-20090047309-A1 | COSMETIC METHODS AND COMPOSITIONS FOR REPAIRING HUMAN SKIN | CUTA, ERCC1, OGG1 | PTGS2 3235/4885CYP1A1 253/4885CYP1B1 269/4885 |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | PTGS2 3950/4885CYP1A1 3389/4885CYP1B1 3055/4885 |
| US-20120225833-A1 | COMPOSITION FOR TREATING MENTAL HEALTH DISORDERS | MAOB, MAOA, DBH | PTGS2 740/4885CYP1A1 271/4885CYP1B1 262/4885 |
| US-20100028317-A1 | Skin Repair Compositions Comprising Circadian Gene Activators And A Synergistic Combination Of Sirt1 Gene Activators | CRY1, PER2, SIRT1 | PTGS2 4175/4885CYP1A1 1738/4885CYP1B1 2054/4885 |
| US-20140256827-A1 | Method Improve Spatial Memory Via Pterostilbene Administration | SQLE, PYGB, CYP11B1 | PTGS2 527/4885CYP1A1 797/4885CYP1B1 588/4885 |
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | PI4KB, HDAC4, PIK3CA | PTGS2 3996/4885CYP1A1 3525/4885CYP1B1 2430/4885 |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | APC, SI, NFKBIA | PTGS2 28/4885CYP1A1 1123/4885CYP1B1 1133/4885 |
| US-20100189795-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | S100A4, TYR, CACYBP | PTGS2 551/4885CYP1A1 4462/4885CYP1B1 4505/4885 |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | PTGS2 2761/4885CYP1A1 3239/4885CYP1B1 1927/4885 |
| US-20160030321-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | S100A4, TYR, CACYBP | PTGS2 551/4885CYP1A1 4462/4885CYP1B1 4505/4885 |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | PTGS2 2856/4885CYP1A1 3460/4885CYP1B1 2991/4885 |
| US-20060025337-A1 | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases | SIRT1, SIRT2, SIRT3 | PTGS2 2589/4885CYP1A1 4534/4885CYP1B1 4690/4885 |
| US-20120288460-A1 | Salicylic Acid Esters of Resveratrol and Cosmetic Compositions | RARA, RARB, RARG | PTGS2 289/4885CYP1A1 1176/4885CYP1B1 1513/4885 |
| US-20060276416-A1 | Methods and compositions for treating flushing and drug induced weight gain | SIRT2, SIRT1, SIRT7 | PTGS2 121/4885CYP1A1 913/4885CYP1B1 1481/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | PTGS2 2688/4885CYP1A1 2787/4885CYP1B1 1879/4885 |
| US-20120288461-A1 | Ascorbic Acid Esters of Resveratrol and Cosmetic Compositions | RARA, RBP4, RARG | PTGS2 2484/4885CYP1A1 540/4885CYP1B1 711/4885 |
| US-20210085640-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | ACAT2, ACAT1, FABP6 | PTGS2 1253/4885CYP1A1 1581/4885CYP1B1 3167/4885 |
| US-20190254943-A1 | HAIR COSMETIC COMPOSITION | CUTA, POLR1C, GRHPR | PTGS2 2392/4885CYP1A1 363/4885CYP1B1 264/4885 |
| US-20080139650-A1 | Fungicidally Active Polymer Dispersions And Use Thereof | CBR3, CBR1, CYP3A4 | PTGS2 3728/4885CYP1A1 5/4885CYP1B1 4/4885 |
| US-20110250251-A1 | Cosmetic Methods And Compositions For Repairing Human Skin | CUTA, ERCC1, OGG1 | PTGS2 3235/4885CYP1A1 253/4885CYP1B1 269/4885 |
| US-20190125052-A1 | METHOD FOR TREATING HAIR | GRHPR, TYR, POLR1C | PTGS2 1194/4885CYP1A1 347/4885CYP1B1 409/4885 |
| US-20140134117-A1 | Butyric Acid Esters Of Resveratrol And Cosmetic Compositions | LRBA, GABRB1, GABRB2 | PTGS2 2648/4885CYP1A1 1189/4885CYP1B1 204/4885 |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | PTGS2 2946/4885CYP1A1 3467/4885CYP1B1 4728/4885 |
| US-20190224093-A1 | HAIR COSMETIC COMPOSITION | CUTA, GRHPR, POLR1C | PTGS2 1901/4885CYP1A1 778/4885CYP1B1 548/4885 |
| US-20160303016-A1 | Valeric Acid Esters Of Resveratrol And Cosmetic Compositions | CUTA, SUV39H1, RARA | PTGS2 2796/4885CYP1A1 348/4885CYP1B1 428/4885 |
| US-10426742-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | PTGS2 2804/4885CYP1A1 3353/4885CYP1B1 2096/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | PTGS2 2946/4885CYP1A1 3467/4885CYP1B1 4728/4885 |
| US-20090035237-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant | SMURF1, CUTA, SMURF2 | PTGS2 3901/4885CYP1A1 2419/4885CYP1B1 2175/4885 |
| US-20100310615-A1 | COMPOSITIONS COMPRISING STILBENE POLYPHENOL DERIVATIVES AND USE THEREOF FOR COMBATING THE AGEING OF LIVING ORGANISMS AND DISEASES AFFECTING SAME | PPARG, PPARA, PC | PTGS2 767/4885CYP1A1 596/4885CYP1B1 499/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | PTGS2 3950/4885CYP1A1 3389/4885CYP1B1 3055/4885 |
| US-20130281413-A1 | Salicylate Conjugates Useful For Treating Metabolic Disorders | HSD17B14, FAH, SORD | PTGS2 334/4885CYP1A1 441/4885CYP1B1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.